Short-term systemic administration of filgrastim during the early postoperative period significantly increased the maximum load to failure of surgically repaired Achilles tendons in female rats evaluated at 28 days. Achilles tendon healing typically involves prolonged extracellular matrix remodeling and an incomplete restoration of native mechanical properties. While granulocyte colony-stimulating factor has been suggested to support tissue repair, its independent effect on tendon healing remained unclear prior to this controlled experimental investigation.
To evaluate the independent biomechanical and structural effects of the agent, the researchers conducted an animal study testing two distinct dosage levels of systemic filgrastim against a control solution following primary tendon repair. The investigation examined whether granulocyte colony-stimulating factor therapy could improve structural tensile strength and promote more favorable histological characteristics during the critical four-week healing window.
The experimental protocol utilized 36 female Wistar albino rats randomly allocated into three equal groups of 12 animals each: a control group, a low-dose filgrastim group receiving 10 µg/kg/day, and a high-dose filgrastim group receiving 30 µg/kg/day. All animals underwent bilateral Achilles tenotomy followed immediately by primary surgical repair. Filgrastim or a 5% dextrose vehicle control was administered subcutaneously once daily for five consecutive days during the early postoperative period.
At postoperative day 28, tissue healing was evaluated through comprehensive biomechanical tensile testing, Updated Bonar histological scoring, and Picrosirius Red polarization birefringence analysis. The investigators also conducted immunohistochemical assessments targeting collagen type I alpha 1 chain, collagen type III alpha 1 chain, and platelet endothelial cell adhesion molecule-1, alongside exploratory serum cytokine measurements. Maximum force was designated as the primary outcome, histological and immunohistochemical parameters served as secondary outcomes, and cytokine profiles were treated as exploratory endpoints, with group comparisons analyzed via one-way ANOVA, Welch’s ANOVA, or Kruskal–Wallis tests.
Biomechanical evaluation revealed that maximum force to failure was significantly higher in both the low-dose cohort (57.49 ± 13.98 N) and the high-dose cohort (62.01 ± 14.64 N) than in the control animals (24.17 ± 11.97 N; p < 0.001 for both comparisons). Notably, there was no statistically significant difference in maximum force between the 10 µg/kg/day and 30 µg/kg/day dosage regimens, indicating that tripling the dose did not produce an additional increase in gross tensile load capacity.
Histological examinations demonstrated that total Updated Bonar scores were lower in both treated cohorts compared to controls, with the lowest scores recorded in the high-dose group, reflecting improved tissue architecture. In addition, filgrastim treatment was associated with a higher red–orange to green birefringence ratio under Picrosirius Red polarization, signaling a higher proportion of mature, organized collagen fibers within the healing repair zone.
Immunohistochemical analysis further supported a more mature remodeling profile in treated tendons. Tendons from animals receiving filgrastim exhibited higher immunoreactivity for collagen type I alpha 1 chain and lower immunoreactivity for collagen type III alpha 1 chain relative to controls, indicating an accelerated transition toward mature collagen architecture. Furthermore, the treated groups demonstrated lower microvessel density as measured by platelet endothelial cell adhesion molecule-1 immunoreactivity, consistent with advanced remodeling progression.
Exploratory serum cytokine assessments revealed nominal alterations among systemic inflammatory markers without broad multi-pathway activation. Specifically, serum interleukin-6 was nominally lower and tumor necrosis factor-α was nominally higher in the high-dose filgrastim group compared to other cohorts, whereas serum levels of interleukin-1β and transforming growth factor-β did not differ significantly across experimental groups.
In their conclusions, the authors noted that early short-term systemic filgrastim administration increased maximum tensile failure load and fostered a more mature histological and immunohistochemical remodeling profile at 28 days post-repair. However, because the higher dose improved selected histological indices without yielding any corresponding increase in mechanical load to failure, the experimental data did not establish a dose–response relationship.
Subject of Research: Biomechanical and histological effects of systemic filgrastim on rat Achilles tendon repair
Article Title: Systemic filgrastim increases maximum load to failure of repaired Achilles tendons in rats: a biomechanical, histopathological, and immunohistochemical study
Article References: Yetkin, H., Ekici, M., & DoÄŸan, M. (2026). Systemic filgrastim increases maximum load to failure of repaired Achilles tendons in rats: a biomechanical, histopathological, and immunohistochemical study. Journal of Orthopaedic Surgery and Research. https://doi.org/10.1186/s13018-026-07342-w
Image Credits: AI Generated
DOI: 10.1186/s13018-026-07342-w
Keywords: filgrastim, Achilles tendon repair, biomechanical testing, maximum load to failure, granulocyte colony-stimulating factor, Wistar albino rats, Updated Bonar score, Picrosirius Red birefringence, collagen type I alpha 1, collagen type III alpha 1, platelet endothelial cell adhesion molecule-1, tenotomy, tissue remodeling, interleukin-6, tumor necrosis factor-alpha, microvessel density
News Source: Ophelia Keating. (November 20, 2026). Systemic Filgrastim Increases Repaired Achilles Tendon Strength in Rat Study. Scienmag.



